An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

類似資料

• Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India
  著者:: Kuttiatt, Vijesh Sreedhar, 等
  出版事項: (2020)
• An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
  著者:: Supali, Taniawati, 等
  出版事項: (2021)
• Epidemiological assessment of eight rounds of mass drug administration for lymphatic filariasis in India: implications for monitoring and evaluation.
  著者:: Subramanian Swaminathan, 等
  出版事項: (2012-01-01)
• Epidemiological Assessment of Eight Rounds of Mass Drug Administration for Lymphatic Filariasis in India: Implications for Monitoring and Evaluation
  著者:: Swaminathan, Subramanian, 等
  出版事項: (2012)
• Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India
  著者:: Subramanian, Swaminathan, 等
  出版事項: (2020)